Supernus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in the treatment of central nervous system (CNS) disorders. The company's business model centers on utilizing proprietary extended-release drug delivery platforms—such as Microtrol, Solutrol, and EnSoTrol—to develop novel formulations of known molecules. By often utilizing the FDA's 505(b)(2) regulatory pathway, Supernus aims to reduce development risk while improving patient adherence and reducing side effects.
Supernus generates the vast majority of its revenue from net product sales in the United States. Its commercial portfolio includes Qelbree (viloxazine), a non-stimulant treatment for ADHD; GOCOVRI (amantadine), for the treatment of dyskinesia in Parkinson's disease patients; and legacy epilepsy and migraine treatments Trokendi XR and Oxtellar XR. In recent years, the company has expanded its portfolio through strategic acquisitions and partnerships, adding products like ZURZUVAE and ONAPGO. In 2024, net product sales accounted for over 96% of total revenues, with the remainder coming from royalty and licensing agreements.
Geographically, Supernus focuses its commercial operations and direct sales force within the United States, while occasionally partnering for international distribution. The company operates in a highly competitive CNS market, competing against both large multinational pharmaceutical companies and specialized neuroscience firms. Supernus maintains its competitive position through its strong intellectual property portfolio, a specialized sales force targeting neurologists and psychiatrists, and a proven track record of reformulating drugs to address unmet medical needs.
